Acute-on-chronic liver failure (ACLF) is a clinical syndrome in patients with chronic liver disease that is associated with multiple organ failures. Several definitions have been developed by expert groups from the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Asian-Pacific Association for the Study of the Liver (APASL).
DelveInsight's "Acute On Chronic Liver Failure (ACLF) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Acute On Chronic Liver Failure (ACLF) market size and shares analysis in the seven major markets (7MM).
Geographies Covered
The report analyses the Acute On Chronic Liver Failure (ACLF) Market trends and developments in the seven major markets (i.e. the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
Acute On Chronic Liver Failure (ACLF) Market Key Facts
- The total Acute-on-Chronic Liver Failure (ACLF) population in 7MM was found to be 60,521 in 2017.
- According to Delveinsight estimates, among the 7MM, Germany accounted for the maximum cases which were 17,100 in 2017.
- The United States had the second-highest population of Acute On Chronic Liver Failure (ACLF) with 12,577 cases. On the other hand, Italy had the lowest population of 1,721 cases in 2017.
- In 2017, Japan accounted for 3,720 cases Acute-on-Chronic Liver Failure (ACLF).
- The number of cases for grade1, grade 2, and grade 3 was found to be 6089, 4810, and 1677 respectively in 2017.
- An estimated 40% to 50% of patients are labeled to have an unrecognized precipitating event leading to ACLF.
Acute On Chronic Liver Failure (ACLF) Market Trends
The Acute On Chronic Liver Failure (ACLF) market analysis section of the report helps to understand the current and forecasted Acute On Chronic Liver Failure (ACLF) Market Trends and Growth by evaluating the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Acute On Chronic Liver Failure (ACLF) Market Size and Shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Acute On Chronic Liver Failure (ACLF) Treatment Market
Currently, there is no specific effective treatment available for patients with Acute On Chronic Liver Failure (ACLF), and therefore, treatment is based on organ support and treatment of associated complications. Central to the treatment of Acute On Chronic Liver Failure (ACLF) is early diagnosis and control of the precipitating factor. The main principles of management for the people affected with Acute On Chronic Liver Failure (ACLF) is to provide support to each of the organs with failure and to promote recovery of the hepatic gland. The current Acute On Chronic Liver Failure (ACLF) treatment includes the use of Devices for detoxification, Antiviral therapy, and Liver transplantation.
The dynamics of the Acute On Chronic Liver Failure (ACLF) market is anticipated to change in the coming years owing to the launch of emerging therapies and the rise in healthcare spending across the world.
Some of the key companies in the Acute On Chronic Liver Failure (ACLF) Market include Yaqrit, Rheacell, Versantis AG, Grifols Therapeutics, Promethera Biosciences, and many others. Acute On Chronic Liver Failure (ACLF) Therapies covered in the report include PE-A 5%, HepaStem, APZ2, VS-01, Dialive, and many more.
Acute On Chronic Liver Failure (ACLF) Epidemiology Forecast
The epidemiology section covers detailed insights about the patient pool for every seven major countries. It helps to recognize the causes of current and forecasted Acute On Chronic Liver Failure (ACLF) Epidemiology Trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Acute On Chronic Liver Failure (ACLF) Epidemiology Segmentation
- Cases of ACLF
- Cases of ACLF by Grades
- Organ failures associated with ACLF
- Potential precipitating events of ACLF
Acute On Chronic Liver Failure (ACLF) Pipeline Insights
The Acute On Chronic Liver Failure (ACLF) Pipeline and Drugs Uptake section focus on the rate of uptake of the market therapies as well as the therapies expected to get launch in the coming years. The analysis covers the Acute On Chronic Liver Failure (ACLF) Market uptake by drugs, patient uptake by therapies, and drug sales.
Report’s drugs uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the Acute On Chronic Liver Failure (ACLF) Therapies based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
For more details, visit: Acute On Chronic Liver Failure (ACLF) Market Trends